Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sj  XXXX .

@entity1 @entity571 @entity146 @entity19 @entity244 @entity2183
OBJECTIVE: Functional antimuscarinic receptor autoantibodies have recently been described in both primary and secondary Sj  @entity244 ( @entity244 ) in a @entity19 bladder contraction assay. Most @entity1 with these antibodies complained of severe lower urinary tract disturbances, which are not a recognized feature of @entity244 . We compared the severity of self-reported urological symptoms, daytime somnolence, and fatigue between a cohort of @entity1 with primary @entity244 and controls with @entity571 ( @entity571 ). METHODS: Female @entity1 were recruited from rheumatology outpatient clinics at 2 hospitals. The American Urological Symptom Index (AUA-7), Epworth Sleepiness Scale, and FACIT-F fatigue self-administered instruments were employed. Results were obtained for 76 @entity1 with primary @entity244 and 43 controls (response rates 85% and 67%, respectively). The @entity1 groups were matched for parity, hormone replacement and diuretic therapy, and number of bladder operations and urinary tract infections, although @entity571 @entity1 were slightly older. RESULTS: AUA-7 urological symptoms were more severe in @entity1 with primary @entity244 compared to @entity571 controls (p = 0.039). Severe urological symptoms were reported by 61% of primary @entity244 @entity1 compared with 40% of @entity571 controls. This difference was predominantly attributable to bladder @entity146 associated with urgency (p = 0.015) and not @entity2183 (p = 0.85). Epworth Sleepiness Scale scores were also more severe in primary @entity244 @entity1 compared to @entity571 controls (p = 0.02), independent of @entity2183 . The FACIT-F fatigue severity scores were not significantly different between @entity1 groups (p = 0.14). CONCLUSION: Urological symptoms and daytime somnolence may be previously unrecognized symptoms of primary @entity244 . These symptoms are consistent with functional disturbances of muscarinic receptors, possibly mediated by muscarinic receptor autoantibodies.
